Cargando…
Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis
BACKGROUND: Long-term antiviral treatments are associated with a significantly lower hepatocellular carcinoma (HCC) incidence in chronic hepatitis B (CHB) patients by reducing HBV DNA concentrations. However, it is still controversial whether antiviral strategies affect HCC development in antiviral...
Autores principales: | Huang, Ze-Hong, Lu, Gui-Yang, Qiu, Ling-Xian, Zhong, Guo-Hua, Huang, Yue, Yao, Xing-Mei, Liu, Xiao-Hui, Huang, Shou-Jie, Wu, Ting, Yuan, Quan, Wang, Ying-Bin, Su, Ying-Ying, Zhang, Jun, Xia, Ning-Shao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930063/ https://www.ncbi.nlm.nih.gov/pubmed/35300634 http://dx.doi.org/10.1186/s12885-022-09413-7 |
Ejemplares similares
-
Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate
por: Ha, Yeonjung, et al.
Publicado: (2020) -
Association between HBs Ag quantification and the risk of hepatocellular carcinoma in patients treated with tenofovir disoproxil fumarate or entecavir
por: Lim, Jung Hyun, et al.
Publicado: (2021) -
Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naïve and experienced patients with chronic hepatitis B
por: Kim, Young Min, et al.
Publicado: (2018) -
Tenofovir Alafenamide Fumarate, Tenofovir Disoproxil Fumarate and Entecavir: Which is the Most Effective Drug for Chronic Hepatitis B? A Systematic Review and Meta-analysis
por: Ma, Xuefeng, et al.
Publicado: (2021) -
Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir
por: Suzuki, Fumitaka, et al.
Publicado: (2014)